Results 201 to 210 of about 27,150 (219)
Some of the next articles are maybe not open access.
Anakinra‐Associated Systemic Amyloidosis
Arthritis & Rheumatology, 2023ObjectiveTo describe a 41‐year‐old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin‐1 receptor antagonist (IL‐1Ra) protein, anakinra, since the age of 28, who presented with golf‐ball size nodules at the anakinra injection sites, early satiety ...
Sara Alehashemi +20 more
openaire +2 more sources
Trends in Pharmacological Sciences, 2001
Data presented at the European League Against Rheumatism 2001 Annual European Congress of Rheumatology suggests the rheumatoid arthritis therapy anakinra can arrest joint destruction in patients with established erosions, improving function, productivity and quality of life. Anakinra is a recombinant form of the interleukin 1 receptor antagonist.
openaire +2 more sources
Data presented at the European League Against Rheumatism 2001 Annual European Congress of Rheumatology suggests the rheumatoid arthritis therapy anakinra can arrest joint destruction in patients with established erosions, improving function, productivity and quality of life. Anakinra is a recombinant form of the interleukin 1 receptor antagonist.
openaire +2 more sources
The use of anakinra in juvenile arthritis
Current Rheumatology Reports, 2005Interleukin-1 (IL-1), one of the major pro-inflammatory cytokines, plays an important role in the pathophysiology and progression of adult and pediatric arthritis. Inhibiting IL-1 activity by using a recombinant human IL-1 receptor antagonist (anakinra) given alone or in combination with methotrexate, moderately reduced the signs and symptoms of active
openaire +2 more sources
Anakinra in the treatment of rheumatic disease
Expert Review of Clinical Immunology, 2006Anakinra is a specific receptor antagonist of interleukin-1 that differs from naturally occurring interleukin-1 receptor antagonist by the presence of a methionine group. It is administered by daily subcutaneous injection. Anakinra improves the clinical signs and symptoms of rheumatoid arthritis, slows radiographic progression and improves patient ...
openaire +3 more sources
Hydrocephalus in CINCA syndrome treated with anakinra
Child's Nervous System, 2006Chronic infantile neurologic, cutaneous, articular (CINCA) syndrome is a rare congenital autoinflammatory disease characterized by neonatal-onset chronic meningitis, hydrocephalus, sensorineural hearing loss, persistent urticarial rash, deforming arthritis, and recurrent fever.
Rigante, Donato +5 more
openaire +3 more sources
Anakinra in rheumatoid arthritis
2005Interleukin-1 (IL-1) plays a central role in the pathophysiology of rheumatoid arthritis (RA) [1]. The IL-1 gene family includes IL-1α, IL-lβ and IL-1 receptor antagonist (IL-IRa) [2], Extracellular IL-lα, which is membrane-associated, and IL- lβ, which is the soluble form, are agonist molecules that can influence the functions of most cell types ...
openaire +2 more sources
Schnitzler's syndrome: Successful treatment with anakinra
Australasian Journal of Dermatology, 2007SUMMARYA 44‐year‐old man presented with a 2‐year history of an intermittent urticarial rash, malaise, weight loss, night sweats, headaches and bone pains. Initial investigations indicated an elevated erythrocyte sedimentation rate, white cell count and a monoclonal immunoglobulin‐M paraprotein.
Rohan Crouch +2 more
openaire +3 more sources
Interstitial granulomatous drug reaction to anakinra
Journal of the American Academy of Dermatology, 2008Interstitial granulomatous drug reactions are an uncommon entity presenting as asymptomatic, annular, erythematous to violaceous plaques. The incidence of such reactions has been increasing with the use of biologic agents. We report, to the best of our knowledge, the first such reaction to the interleukin (IL)-1 inhibitor anakinra.
Loren E. Clarke +6 more
openaire +3 more sources
Anakinra Treatment of Patients with Rheumatoid Arthritis
The Annals of Pharmacotherapy, 2002OBJECTIVE: To summarize the safety data arising from clinical trials of anakinra, a human recombinant form of interleukin-1 receptor antagonist (IL-1Ra) developed for the treatment of rheumatoid arthritis (RA). DATA SOURCES: Primary articles and abstracts identified through the National Library of Medicine's PubMed database (1982–2001) and secondary ...
openaire +3 more sources
Anakinra in Creutzfeldt-Jakob disease
Acta Neurologica Belgica, 2022Giuseppe Bomboi +4 more
openaire +2 more sources